U.S./EU Business Groups Call For Japan Health Policy Overhaul
This article was originally published in PharmAsia News
Two major foreign business groups in Japan have released a new White Paper on Health Policy that includes close to 200 proposals designed to improve the cost-efficiency of the Japanese healthcare system, labor productivity and ultimately economic growth.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.